ArticleCancer cell2023
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade.Cancer discovery · 2026Article
- Current Status of the Diagnosis and Treatment of Mismatch Repair Deficient Colorectal Cancer.Biomedicines · 2026Review
- High PMS2 Expression-Based Nomogram for Risk Stratification in Resected Hepatocellular Carcinoma: Application to Recurrence and Neoadjuvant Therapy Selection.Journal of Cancer · 2026Article
- Mismatch repair protein imbalance in head and neck squamous cell carcinoma: associations with clinical features and survival.Therapeutic advances in medical oncology · 2026Article
- Disruption of protein-protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency.NAR cancer · 2025Article
- Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in Cancer.Cancer research · 2025Review
- Review
- Article
- LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8Cancer immunology, immunotherapy : CII · 2025Article
- Colorectal Cancer: Pathogenesis and Targeted Therapy.MedComm · 2025Review
- Identification of Fanconi anemia pathway genes as novel prognostic biomarkers and therapeutic targets for breast cancer.Translational cancer research · 2025Article
- PD-L1 expression and mismatch repair deficiency in locally advanced head and neck squamous cell carcinoma treated with chemoradiotherapy: association with treatment response and survival.Frontiers in immunology · 2025Article
- Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer.Human vaccines & immunotherapeutics · 2024Review
- DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.British journal of cancer · 2024Review
- Early-onset cancers: Biological bases and clinical implications.Cell reports. Medicine · 2024Review
- Mechanisms of metastatic colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.EBioMedicine · 2024Article
- Molecular characterization analysis of PANoptosis-related genes in colorectal cancer based on bioinformatic analysis.PloS one · 2024Article
- Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.Frontiers in immunology · 2024Review
- Genomic instability as a driver and suppressor of anti-tumor immunity.Frontiers in immunology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
Abstract
Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.